Zheng Quan Zhi Xing·2025-07-21 00:08Group 1: Bid Medicine - Bid Medicine emphasizes capital operations and resource integration as key strategic focuses for future development, aiming to expand global business through various means and continuously seek acquisition opportunities [1] - The company has completed its global market layout, established multiple regional centers, and upgraded its U.S. warehouse and R&D center, resulting in rapid growth in overseas business [1] - Bid Medicine is facing a 20% fentanyl tax and a small 10% equivalent tariff on products sold in the U.S., but it has managed to pass on costs through price increases and discount adjustments, leading to minimal impact [1] - The company perceives a gradual recovery in industry demand, with improving orders from overseas and ongoing stimulation of market growth due to domestic innovative drug policies [1] Group 2: Medicy - Medicy is strengthening key technology research for hot drug development and building multiple innovative technology service platforms covering CGT, nucleic acid drugs, and PROTC [2] - The company has taken measures to ensure stable supply of experimental monkeys and has established a research laboratory in Boston, enhancing its overseas market expansion [2] - Medicy is focusing on talent development, optimizing internal organization and talent structure, and aims to improve operational conditions through cost reduction, efficiency enhancement, and strengthened R&D capabilities [2] - The domestic CRO industry is expected to benefit from policy support and the advancement of innovative drug development [2]